Developing Innovative
Computationally Designed VLP Vaccines

By utilizing computationally designed proteins that self-assemble into virus-like particles (VLPs), we are able to readily manufacture VLPs displaying complex antigens to target significant unmet medical needs.

RSV and Covid-19 Vaccines
Our vaccine candidates for respiratory syncytial virus (RSV) and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which causes COVID-19, have the potential to induce high neutralizing antibody titers for more effective protection.
Icosavax is dedicated to advancing vaccines against severe life-threatening respiratory diseases to protect our most at-risk populations.
In the News

Icosavax, Inc.

1616 Eastlake Avenue E. Suite 208 
Seattle, WA 98102

  • White Twitter Icon
  • White Facebook Icon
  • White LinkedIn Icon

© 2020 Icosavax, Inc. All rights reserved.